Relevance of MIA and S-100 to monitor BRAF inhibitor (iBRAF) therapy in metastatic melanoma patients.

Authors

null

Miguel F. Sanmamed

Department of Oncology, University of Navarra, Pamplona, Spain

Miguel F. Sanmamed , Sara Fernandez-Landazuri , Eduardo Castanon , Jose Echeveste , Maria D. Lozano , Miguel A. Idoate , Jose Luis Perez-Gracia , Alvaro Gonzalez , Salvador Martin-Algarra

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Melanoma/Skin Cancers

Citation

J Clin Oncol 31, 2013 (suppl; abstr 9074)

DOI

10.1200/jco.2013.31.15_suppl.9074

Abstract #

9074

Poster Bd #

48E

Abstract Disclosures

Similar Posters

Poster

2023 ASCO Annual Meeting

A powerful drug combination strategy targeting BRAF-mutant melanoma.

A powerful drug combination strategy targeting BRAF-mutant melanoma.

First Author: Luke Daniel Rothermel

First Author: Matthew Dankner

Poster

2016 ASCO Annual Meeting

Real-world overall survival in advanced melanoma from the IMAGE study.

Real-world overall survival in advanced melanoma from the IMAGE study.

First Author: Mark R. Middleton

First Author: Friedegund Elke Meier